Status:
NOT_YET_RECRUITING
A Prospective Single-Arm Observational Study of Maribavir for the Treatment of Post Hematopoietic Stem Cell Transplantation Cytomegalovirus Infection
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Conditions:
Infections, Cytomegalovirus
Eligibility:
All Genders
12+ years
Brief Summary
The main aim of this study is to check the effectiveness and safety of maribavir for the treatment of CMV infection after HSCT in Chinese patients in real-world settings. The participants will be tre...
Eligibility Criteria
Inclusion
- Hematopoietic Stem Cell Transplant Recipients
- Adult patients with an expected survival of ≥4 weeks.
- Confirmed CMV infection, including CMV viremia and CMV disease.
- Fully understand the content of the trial, voluntarily participate and complete the trial, and voluntarily sign the informed consent form.
Exclusion
- Participants who meet any of the following criteria are not eligible for this study:
- Patients currently participating in other CMV-related clinical studies, such as those receiving anti-CMV drug treatment or involved in CMV vaccine clinical studies.
- At screening, liver function tests show: AST \> 5×ULN, or ALT \> 5×ULN, or total bilirubin ≥ 3.0×ULN.
- Patients with psychiatric disorders or severe psychological conditions that may affect the ability to provide informed consent or participate in follow-up consultations.
- Participants deemed unsuitable for inclusion by the investigator.
Key Trial Info
Start Date :
September 25 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 31 2027
Estimated Enrollment :
17 Patients enrolled
Trial Details
Trial ID
NCT07141095
Start Date
September 25 2025
End Date
January 31 2027
Last Update
August 26 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China